Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Legend Biotech (LEGN) Stock Price & Analysis
255 Followers
LEGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$42.08 - $77.32
Previous Close$45.76
Volume1.05M
Average Volume (3M)1.03M
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$383.94M
Price to Earnings (P/E)-17.6
Beta0.56
Next Earnings
Aug 30, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding181,911,035
10 Day Avg. Volume843,618
30 Day Avg. Volume1,029,658
Standard Deviation0.14
R-Squared0.00198
Alpha0.00787
Financial Highlights & Ratios
Price to Book (P/B)6.47
Price to Sales (P/S)29.19
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$85.00Price Target Upside83.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Legend Biotech News
PremiumCompany Announcements
Legend Biotech’s Strong Q1 Growth and Strategic Expansion
PremiumCompany Announcements
European Approval for Legend Biotech’s Myeloma TreatmentBulls Say, Bears Say
Bulls Say
Financial StabilityThe company ended the quarter with a strong cash position, which provides a solid financial foundation for continued growth and investment in new therapies.
Manufacturing EfficiencyCompany expects outpatient administration to double by year-end from the current one-third level, indicating potential for increased market penetration.
Market PenetrationCarvykti is expected to achieve approximately 20% penetration in 2-4L treatment based on positive physician surveys and a significant portion of high-risk patients.
Bears Say
Financial PerformanceLegend recorded a 1Q24 net loss of $59.8M, wider than the estimated net loss.
Product Safety ConcernsThe updated Carvykti label includes increased early mortality in several sections of its documentation.
Sales PerformanceCarvykti Q1 revenue was flat at $157M, missing consensus estimates by 6.5%.
---
Ownership Overview
0.00%
Insiders
18.29% Mutual Funds
22.24% Other Institutional Investors
59.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $42.08 and its highest was $77.32 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Currently, no data Available
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Aug 30, 2024 which is in 105 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on May 13, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.033.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -$0.29.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 181,911,040 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went down -0.624%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Among the largest hedge funds holding Legend Biotech Corporation’s share is RA Capital Management. It holds Legend Biotech Corporation’s shares valued at 377M.
---
Legend Biotech Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.00 (83.31% Upside)
$85.00 (83.31% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 83%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 174.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.43%
12-Months-Change
Fundamentals
Return on Equity
-51.28%
Trailing 12-Months
Asset Growth
46.78%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
---
LEGN Earnings Call
Q1 2024
0:00 / 0:00
---
LEGN Stock 12 Month Forecast
Average Price Target
$85.00
▲(83.31% Upside)
Technical Analysis
Best Analysts Covering LEGN
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
-1.88%
reiterated a buy rating last month
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -1.88% per trade.
---